An acquisition last year by a Pacific Northwest biotech company has paid off, in the form of a successful registration-directed breast cancer study. The company – which is based in the suburb of ...
COPENHAGEN, Sept 14 (Reuters) - Danish biotech company Genmab A/S will collaborate in cancer drug research with Seattle Genetics under a strategy to focus on strategic partnerships for drug ...
-Collaboration Combines Seattle Genetics’ Expertise in Cancer Targets and Antibody-Based Therapies with Unum’s Novel Antibody-Coupled T-cell Receptor (ACTR) Technology- -Companies to Focus on the ...
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2017. The company also highlighted ADCETRIS ...
Fintel reports that Capital International Investors has filed a 13G/A form with the SEC disclosing ownership of 18.06MM shares of Seattle Genetics, Inc. (SGEN). This represents 9.7% of the company. In ...
Seattle Genetics (SGEN) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.74 per share a year ago. These figures are ...
Clay Siegall is the founder and CEO of Seattle Genetics. Anthony Bolante | PSBJ To continue reading this content, please enable JavaScript in your browser settings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results